C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion. Artificial intelligence (AI) is transforming the way companies operate.

Should you invest $1,000 in C3.ai right now? Before you buy stock in C3.ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Big Names Fall Off the Cliff. C3.ai, Inc. (NYSE:AI) is one of the worst-performing stocks on Thursday. C3 AI snapped a two-day rally on Thursday, losing 10.84 percent to close at $26 apiece as ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Investing.com -- Teleperformance (EPA: TEPRF) shares plunged more than 16% on Friday after the company cut its full-year revenue outlook, reported weaker-than-expected margins and missed earnings ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

Rising demand for energy-efficient processes and stricter emission norms are boosting global adoption of licensed chemical technologies and innovations.Austin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The ...